Sun Pharmaceutical Industries Ltd has received a covenant of 'not to sue' from Wyeth over Sun Pharma's Abbreviated New Drug Application (ANDA) for generic venlafaxine extended release tablets with multiple para IV certifications.
This ANDA for generic venlafaxine extended release tablets, AB-rated equivalent of Wyeth's Effexor capsules, includes three strengths, 37.5 mg, 75 mg and 150 mg and is based on Innovative technology for extended release tablets. These strengths of Effexor capsules have annual sales approximately US $2.6 billion in the US.
As per the covenant, Wyeth covenants not to sue Sun under any claims of US Patent Nos. 6,274,171, 6,4013,120 and 6,419,958.
Venlafaxine is an antidepressant of the serotonin-noreplnephrine reuptake inhibitor (SNRI) class.